Cystic Fibrosis Clinical Trials in Atlanta, Georgia

6 studies are recruiting for cystic fibrosis in Atlanta, Georgia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Streamlined Treatment of Pulmonary Exacerbations in Pediatrics

   The STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient pulmonary exacerbations (PEx) in the pediatric CF population.

   Stage

   Not phased

   Ages

   3 to 18

   Site

   Children's Healthcare of Atlanta & Emory University, Atlanta, Georgia

   Locations

   33 in total

   Run by

   University of Washington, the Collaborative Health Studies Coordinating Center

   See if you can join NCT06654752 on ClinicalTrials.gov

2. Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study

   The purpose of this study is to look at pulmonary exacerbations in people with cystic fibrosis (CF) that need to be treated with antibiotics given through a tube inserted into a vein (intravenous or IV). A pulmonary exacerbation is a worsening of respiratory symptoms in people with CF that needs me…

   Stage

   Phase 4

   Ages

   6 and older

   Site

   Emory University, Atlanta, Georgia

   Locations

   60 in total

   Run by

   Chris Goss

   See if you can join NCT05548283 on ClinicalTrials.gov

3. FEED-Cystic Fibrosis (FEED-CF)

   The goal of this study is to determine the extent to which excess dietary sugars serve as a precipitating factor in glucose intolerance in adults with cystic fibrosis (CF), a population at especially high risk for a unique form of diabetes (CF-related diabetes, CFRD) and with standard-of-care dieta…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Emory University Hospital, Atlanta, Georgia

   Run by

   Emory University

   See if you can join NCT05766774 on ClinicalTrials.gov

4. Role of Body Fat Distribution in Metabolic and Pulmonary Decline in Cystic Fibrosis (ORBIT-CF)

   Nutrition and body composition, the amount of muscle and fat in the body, has a role in overall health. This study wants to learn more about how nutrition and body composition affects health outcomes like glucose tolerance and lung function in patients with cystic fibrosis (CF) who are ages 16-30 y…

   Stage

   Not phased

   Ages

   16 and older

   Site

   Emory University/Children's Hospital of Atlanta (CHOA), Atlanta, Georgia

   Locations

   2 in total

   Run by

   Emory University

   See if you can join NCT04002882 on ClinicalTrials.gov

5. Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)

   RETRIAL is a multi-site observational study of people with Cystic Fibrosis (PWCF) ages 6 and up starting the new triple-therapy modulator (vanzacaftor/tezacaftor/deutivacaftor (VTD)), after having experienced neuropsychiatric events and/or liver injury while taking elexacaftor/tezacaftor/ivacaftor …

   Stage

   Not phased

   Ages

   6 and older

   Site

   Emory University, Atlanta, Georgia

   Locations

   18 in total

   Run by

   Boston Children's Hospital

   See if you can join NCT06683092 on ClinicalTrials.gov

6. A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators

   The REACH study is for people with CF who do not take cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The goal of the REACH study is to collect research data, including health data and specimens, from people with CF who do not take CFTR modulators. This data may be used to in…

   Stage

   Not phased

   Ages

   12 and older

   Site

   Children's Healthcare of Atlanta and Emory University, Atlanta, Georgia

   Locations

   68 in total

   Run by

   Nicole Hamblett

   See if you can join NCT06504589 on ClinicalTrials.gov